阿格列汀联合二甲双胍治疗2型糖尿病合并非酒精性脂肪肝的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Alogliptin combined with Metformin in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver(NAFLD).Methods A total of 60 patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver treated in our hospital from May 2017 to May 2018 were selectes as the subjects,and divided into observation group and control group by random number table method,with 30 cases in each group.The control group was treated with metformin.The observation group was treated with Aglutine combined with Metformin.The baric index(BMI),fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),aspartate aminotransferase(AST),alanine aminotransferase(ALT),gamma-glutamyl transpeptidase(GGT),total cholesterol(TC),triacylglycerol(TG)and fatty liver clinical effects,adverse reactions were observed.Results BMI,FRG,2 hPG and HbAlc of the two groups after treatment were lower than those before treatment,and the BMI,FRG,2 hPG and HbAlc of the observation group were lower than those of the control group,and the differences were statistically significant(P＜0.05).AST,ALT,GGT,TC,TG of the two groups after treatment were lower than those before treatment,and the AST,ALT,GGT and TG of the observation group were lower than those of the control group,and the differences were statistically significant(P＜0.05).The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Agliptin combined with Metformin has obvious effect on type 2 diabetes mellitus complicated with NAFLD.It can effectively control blood glucose,improve liver function,and is safe.It is worthy of clinical application.

Key words： Type 2 diabetes mellitus Nonalcoholic fatty liver disease A Glenn Dean Metformin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Ying
	YU Hong-ying

Cite this article:

LIU Ying,YU Hong-ying. Clinical effect of Alogliptin combined with Metformin in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver[J]. 中国当代医药, 2019, 26(2): 55-57.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I2/55

[1]	阮勇，王秀景，谭擎缨，等.西格列汀治疗初发2型糖尿病伴非酒精性脂肪肝的疗效及对患者血糖、血脂的影响[J].中国药师，2015，18（7）：1160-1162.
[2]	刘香兰，胡朝晖，刘加和.西格列汀联合二甲双胍治疗新诊断2型糖尿病伴非酒精性脂肪肝的疗效观察[J].现代实用医学，2016，28（7）：894-895.
[3]	胡田颖，郭伟.西格列汀联合二甲双胍对2型糖尿病合并非酒精性脂肪肝的疗效及安全性[J].药物评价研究，2017，40（6）：844-847.
[4]	李丹丹.二甲双胍联合阿格列汀治疗2型糖尿病患者的临床观察[J].中国民康医学，2016，28（5）：46-47.
[5]	赵跃萍，刘静，邰贺，等.阿格列汀联合二甲双胍对2型糖尿病患者球后动脉血流动力学及氧化应激指标的影响[J].现代中西医结合杂志，2016，25（11）：1163-1166.
[6]	周岩，姬秋和.阿格列汀在2型糖尿病治疗中的研究进展[J].中华内分泌代谢杂志，2014，30（10）：868-871.
[7]	王瑜，胡明，占美，等.阿格列汀治疗2型糖尿病的系统评价[J].中国医院药学杂志，2014，34（23）：2014-2022.
[8]	董茜妍，旷劲松.阿格列汀对经二甲双胍治疗的肥胖2型糖尿病患者外周血氧化相关物质活性的影响[J].检验医学与临床，2016，13（3）：328-331.
[9]	翁洋，王吉魁，宋雨凌，等.阿格列汀联合二甲双胍治疗2型糖尿病合并非酒精性脂肪肝的疗效和安全性分析[J].实用药物与临床，2016，19（6）：713-715.
[10]	卢海波，戴德银，刘羽，等.阿格列汀临床应用研究进展[J].中国药业，2015，24（21）：255-256.
[11]	张四青，习燕华，钟树妹，等.格列美脲联合二甲双胍对新诊断2型糖尿病伴非酒精性脂肪肝病患者胰岛素抵抗和胰岛β细胞功能的影响[J].中国全科医学，2016，19（5）：525-528.
[12]	董慧，田坚，张盈妍，等.沙格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床效果[J].广西医学，2017，39（3）：316-318.
[13]	李锦华，王娜.沙格列汀联合二甲双胍治疗2型糖尿病临床疗效的系统评价[J].中国老年学杂志，2016，36（5）：1102-1104．
[14]	陈珺秋，余润芬.沙格列汀单药治疗2型糖尿病的疗效观察[J].中外医学研究，2016，14（15）：128-129．
[15]	曾鑫．沙格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床研究[J].中国现代药物应用，2016，10（14）：131-132．